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Abstract
Background: Over-prescribing of benzodiazepines appears common in many countries, a better
understanding of prescribing practices and attitudes may help develop strategies to reduce
prescribing. This study aimed to evaluate benzodiazepine prescribing behaviour and attitudes in
general practitioners practising in Chiang Mai and Lampoon, Thailand.
Methods: Questionnaire survey of general practitioners in community hospitals, to estimate: i) use
of benzodiazepines for anxiety/insomnia, panic disorder, depression, essential hypertension, and
uncomplicated low back pain and ii) views on the optimal duration of benzodiazepine use.
Results: Fifty-five of 100 general practitioners returned the completed questionnaires. They
reported use of benzodiazepines for anxiety/insomnia (n = 51, 93%), panic disorder (n = 43, 78%),
depression (n = 26, 43%), essential hypertension (n = 15, 27 %) and uncomplicated low back pain
(n = 10, 18%). Twenty-eight general practitioners would prescribe benzodiazepines for non-
psychiatric conditions, 17 for use as muscle relaxants. Seventy-five per cent, 62% and 29% of the
general practitioners agreed or totally agreed with the use of benzodiazepines for insomnia, anxiety
and depression, respectively. Practitioners agreed that prescribing should be less than one week
(80%); or from 1 week to 1 month (47%); or 1 to 4 months (16%); or 4 to 6 months (5%) or more
than 6 months (2%). Twenty-five general practitioners (45%) accepted that they used
benzodiazepines excessively in the past year.
Conclusion: A considerable proportion of general practitioners in Chiang Mai and Lampoon,
Thailand inappropriately use benzodiazepines for physical illnesses, especially essential
hypertension and uncomplicated low back pain. However, almost half of them thought that they
overused benzodiazepines. General practitioner's lack of time, knowledge and skills should be
taken into account in improving prescribing behaviour and attitudes.
Background
Benzodiazepines (BZDs) are approved for treating clini-
cally significant anxiety and insomnia. They have a better
safety profile in comparison to barbiturates – their
Published: 23 June 2005
BMC Family Practice 2005, 6:27 doi:10.1186/1471-2296-6-27
Received: 22 November 2004
Accepted: 23 June 2005
This article is available from: http://www.biomedcentral.com/1471-2296/6/27
© 2005 Srisurapanont et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 5
(page number not for citation purposes)
BMC Family Practice 2005, 6:27 http://www.biomedcentral.com/1471-2296/6/27predecessors, and many physicians have overestimated
their safety. It is now widely accepted that BZD prescribing
has many risks, including tolerance, dependence and mis-
use, as well as BZD-induced depression, cognitive impair-
ment, disinhibition and psychomotor impairment [1].
BZD has become more restricted recently. The UK data
sheets for diazepam and temazepam recommend that
BZD should be used for short-term (2 – 4 weeks) manage-
ment. They are unlikely to be efficacious in the treatment
of anxiety after 4 months [2]. BZD addiction can occur
when doses within the clinical range are taken regularly
over about 6 months [3]. In addition, a recent review sug-
gests that, even in general anxiety disorder – a major indi-
cation for BZDs – this treatment may do more harm than
good [4].
BZD use has been studied in high income countries, and
it appears that prescribing levels have come down as the
risks of addiction and adverse effects have become more
widely publicised [5]. However, little research has been
carried out in developing countries. Limited evidence sug-
gests that BZD use is common in these countries. A recent
community survey in Lebanon found that 9.6% (N =
1000) of the population had taken BZD in the previous
month [6]. This study also found that approximately 30%
of BZD users took these medications for more than 12
months. Although many developing countries allow
BZDs to be sold over-the-counter in pharmacies, a litera-
ture review of BZD use in Brazil found that the vast major-
ity of BZD consumption was due to medical prescription
[7].
While psychiatrists are specialised in caring for people
with mental health and substance use problems, their
numbers are very limited, especially in developing coun-
tries. Therefore, GPs play an important role in prescribing
BZDs. For example, a survey in Chile found that 69% of
those taking BZDs received the medications from commu-
nity clinics [8]. A cross-sectional study of prescriptions in
3,368 patients visiting a primary health unit in Brazil also
showed that 20.6% of prescriptions included BZDs [9]. A
survey of community hospitals in a rural area of Thailand
demonstrated that 15% of all adult outpatients received
benzodiazepines [10]. These results seem to agree with a
previous questionnaire survey among Thai GPs, which
found that approximately 50% of them prescribed BZDs
for more than 25% of their patients [11]. As there is a
trend to increase the provision of mental health care at the
primary care level [12], GPs may prescribe more BZDs in
the future.
A survey of BZD prescribing practice and attitudes would
increase understanding of BZD prescribing problems,
important in developing a strategy to reduce BZD pre-
scribing. We therefore proposed to evaluate the prescrib-
ing behaviour and attitudes of GPs practicing in Northern
Thailand. Two major foci of the survey were the indica-
tions for and appropriate duration of BZD treatment.
Because most GPs in developing countries are overloaded
by a large number of patients in their everyday practice,
patient medical records, e.g. diagnosis, are usually not
completed or inaccurate. We therefore decided to conduct
a survey using mailed questionnaires.
This survey concerned only the GPs' practice at public set-
tings, where pharmacists take a role in dispensing the pre-
scribed drugs, and GPs practice as non-dispensing
physicians. This decision was made because most Thai
physicians have their own private practice and are allowed
to dispense almost all prescribed drugs, including BZDs,
in their private settings. The results of a previous study
have shown that dispensing and non-dispensing physi-
cians have different patterns of prescribing [13].
Methods
Study population
Questionnaire survey to all 100 general practitioners
working in community hospitals located in Chiang Mai
and Lampoon, Northern Thailand.
Questionnaire
The questionnaire for this study included four parts:
i) GP's were asked to say whether they would prescribe
BZDs and/or brief (3–5 minutes) supportive psychother-
apy/advice for five case vignettes of anxiety/insomnia fol-
lowing a stressful life event, panic disorder, depression,
essential hypertension and uncomplicated low back pain
(see Annex). Brief supportive psychotherapy/advice could
be given by the GPs or other medical professionals in the
community hospitals.
ii) GPs were asked whether they agreed with the use of
BZDs for clinically significant insomnia, anxiety and
depression, as well as non-psychiatric illnesses, by using a
10 cm line of visual analogue scale (VAS) ranging from
totally disagree to totally agree. A VAS score of 0.00–1.9,
2.0–3.9, 4.0–6.0, 6.1–8.0, and 8.1–10.0 were classified as
totally disagree, disagree, neutral, agree and totally agree,
respectively.
iii) the same VAS and its scoring system were used to ask
the GPs whether they agreed with the regular use of BZDs
for less than 1 week, 1 week to 1 month, more than 1
month to 4 months, more than 4 months to 6 months
and more than 6 months.Page 2 of 5
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scribed BZDs and if so why (more than one reason could
be chosen).
Procedures
The GPs were informed that the survey did not intend to
assess their knowledge but wished to understand their
practice. The answers should be based on their everyday
practice in public settings only (mainly community hospi-
tals). The GPs were also asked to return the questionnaires
with no answer if: i) they did not wish to respond or ii)
they saw less than five adult out-patients per week.
To maximize responses, 6 weeks after the first mailing, we
sent the questionnaire to all GPs who had not replied. Six
weeks after the second mailing, we sent the questionnaire
for the third (and last) time to GPs who had still not
responded. The survey was carried out between July and
November 2003.
Statistical analysis
Descriptive statistics (percentages, means and standard
deviations) were calculated.
Results
Fifty-eight of 100 GPs (58%) returned the questionnaires
to us. Three were excluded; two GPs refused to answer the
questionnaire, and another one saw less than five adult
patients per week. Questionnaires from 55 GPs (32 males
and 23 females) were subsequently analyzed. The GPs
mean (SD) age in years was 31.6 (7.1), with a mean of 6.7
(5.8) years in practice and working for an average of 38.7
(18.2) hours per week. The mean number of patients seen
per week (SD) was 392.8 (243.9). Of 13 GPs who had spe-
cial training, four were paediatricians, three were
internists, two each were surgeons and orthopaedists, and
there was one family practitioner and one obstetrician/
gynaecologist.
Table 1 shows the number of GPs giving BZDs and brief
supportive psychotherapy/advice for the 5 case vignettes.
The majority of GPs would give BZDs for anxiety/insom-
nia following a stressful life event and panic disorder. The
numbers of GPs giving brief supportive psychotherapy/
advice for anxiety/insomnia and panic disorder were
lower (22% and 15%, respectively). While 47% of the GPs
would give BZDs for depression, 27% and 18% would
give BZDs for essential hypertension and uncomplicated
lower back pain, respectively. Of 26 GPs (47% of the GPs)
who gave BZDs for depression, 16 of them would admin-
ister antidepressants concurrently.
Agreement on the indications and durations of BZD use
are shown in Table 2. In respect to indications, 75%, 62%
and 29% of the GPs agreed or totally agreed with the use
of BZD for insomnia, anxiety, and depression, respec-
tively. Twenty-eight GPs specified the use of BZDs for
nonpsychiatric illnesses, especially the use of BZDs as
muscle relaxants in 17 GPs. Eighty percent, 47%, 16%, 5%
and 2% of the GPs agreed or totally agreed with the regu-
lar treatment of BZD for less than 1 week, 1 week – 1
month, more than 1 month – 4 month, more than 4
months – 6 months and more than 6 months,
respectively.
Twenty-five GPs (45.5%) accepted that they excessively
used BZDs in the past year. The reasons for the over-pre-
scribing were lack of time (17 responses), lack of knowl-
edge and skills (14 responses), intention to keep doctor-
patient relationship (i.e., patient demand -13 responses),
lack of alternative treatment to BZDs (12 responses) and
saving costs (10 responses).
Discussion
This survey was conducted in young Thai GPs practicing
in community hospitals. One of the surprising findings
was these doctors reported that they would use BZDs for
essential hypertension and uncomplicated low back pain,
as well as the use as muscle relaxants. Almost half of the
GPs agree that they over-prescribe BZDs.
BZD prescribing for essential hypertension and low back
pain is relatively common in developing countries [10].
Although there is some evidence supporting the benefits
of BZDs for these conditions [14-16], the administration
of these drugs may be detrimental [17]. This practice
Table 1: Number of GPs giving BZDs and brief supportive psychotherapy or medical advices for the 5 case vignettes (N = 55)
Clinical conditions No. of GPs (%) giving BZDs No. of GPs (%) giving brief supportive 
psychotherapy or advice
1. Stressful life event and anxiety and insomnia 51 (92.7) 39 (70.9)
2. Panic disorder 43 (78.2) 35 (63.6)
3. Depression 26 (47.2) 29 (52.7)
4. Essential hypertension 15 (27.3) 46 (83.6)
5. Uncomplicated low back pain 10 (18.2) 38 (69.1)Page 3 of 5
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preferred risk/benefit profiles are widely available, e.g.,
propanolol, orphenadrine citrate.
The results of this and previous studies [18] demonstrate
that BZD prescribing is a dilemma for GPs. Many of them
realize the harmful effects of BZDs, but cannot control
their prescribing. Improvement of knowledge and skills
alone may not solve the problem. GPs in this survey have
to see approximately 10 patients per hour, and this time
pressure should be taken into account in developing any
strategy to solve the problem.
The findings of this survey are helpful in developing a
strategy to reduce BZD use, especially among GPs practic-
ing in developing countries. Because almost half of the
GPs have already identified BZD prescribing as a problem,
a simple and practical strategy to reduce prescribing
would be welcomed. As lack of knowledge and skills con-
tributes to the problem, an educational programme
should be a part of the strategy. Firm evidence showing
that fluoxetine can be used to treat patients with anxiety
and/or depression safely and cost-effectively in primary
care settings of low-income countries [19] should be pre-
sented to the GPs. GPs perceived causes of BZD over-pre-
scribing, e.g., lack of knowledge and skills, lack of
alternative treatment to BZDs and saving cost of treat-
ment, could be solved. Improving GPs' communication
and training other health professionals, e.g., nurses, to
provide brief supportive psychotherapy/advice may be
also helpful, especially, in maintaining health profes-
sional-patient relationship. In addition, this can be used
as an alternative or an adjunct to BZD treatment. Because
sufficient consultation time is a key for quality patient
care, it should be kept in mind that the impact of any strat-
egy may be reduced if this problem cannot be mitigated.
Some limitations should be considered in interpreting the
study findings. First, a questionnaire survey may not
reflect the 'real world' practice. As most physicians have
realized the detrimental effects of BZDs, the answers of
many respondents may be based on their knowledge, or
what they perceive to be 'best practice', but not their actual
practice. Due to this limitation, we focus our interpreta-
tion and discussion only on outstanding findings, e.g., the
use of BZDs for physical illnesses, the acceptance of BZD
over-prescribing. Second, the moderate response rate
(58%) of this survey may have some impact on the valid-
ity of this study. Third, the results of present study may
not be widely applicable because the GPs in Thailand may
have different backgrounds from those in other parts of
the world, e.g., culture, education, health care systems.
However, the findings may provide insight for further
studies elsewhere particularly developing countries. Last,
most (16 of 26) GPs who gave BZDs for treating depres-
sion would also administer antidepressants concurrently.
BZDs and anti-depressants should not be co-prescribed
for longer than four weeks [20]. As the survey did not
assess duration of BZD co-prescribing in depressed
patients, we cannot determine the appropriateness of
these co-prescriptions.
Conclusion
This survey found that a considerable proportion of GPs
in Chiang Mai and Lampoon, Thailand inappropriately
use BZDs for physical illnesses, especially essential hyper-
tension and uncomplicated low back pain. However,
many GPs are aware that they over-prescribe BZDs. The
problems of lack of time, knowledge and skills should be
taken into account in improving the prescribing behav-
iour and attitude.
List of abbreviations
BZD = benzodiazepine
GP = general practitioner
VAS = visual analog scale
Table 2: Agreement on the use of BZD assessed by using a 10 cm line of visual analogue scale from totally disagree to totally agree*
Issues Totally disagree, n (%) Disagree, n (%) Neutral, n (%) Agree, n (%) Totally agree, n (%)
1. For clinically significant insomnia 2 (3.6) 1 (1.8) 11 (20.0) 14 (25.5) 27 (49.1)
2. For clinically significant anxiety 7 (12.7) 4 (7.3) 10 (18.2) 15 (27.3) 19 (34.5)
3. For clinically significant depression 16 (29.1) 11 (20.0) 12 (21.8) 5 (9.1) 11 (20.0)
4. For regular use of less than 1 week 2 (3.6) 1 (1.8) 8 (14.5) 13 (23.6) 31 (56.4)
5. For regular use of 1 week – 1 month 15 (27.3) 2 (3.6) 12 (21.8) 15 (27.3) 11 (20.0)
6. For regular use of more than 1 month – 4 
months
28 (50.9) 10 (18.2) 8 (14.5) 5 (9.1) 4 (7.3)
7. For regular use of more than 4 months – 6 
months
39 (70.9) 9 (16.4) 4 (7.3) 1 (1.8) 2 (3.6)
8. For regular use of more than 6 months 47 (85.5) 4 (7.3) 3 (5.5) 0 (0.0) 1 (1.8)
*A VAS score of 0.00–1.9, 2.0–3.9, 4.0–6.0, 6.1–8.0, and 8.1–10.0 were classified as totally disagree, disagree, neutral, agree, and totally agreePage 4 of 5
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